LEO 138559 placebo

DRUG3 trials

Sponsors

LEO Pharma

Conditions

Atopic Dermatitis

Phase 1

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

CompletedNCT03514511

LEO PharmaAtopic Dermatitis

Start: 2018-05-07End: 2021-03-02Updated: 2025-02-24

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

CompletedNCT05099133

LEO PharmaAtopic Dermatitis

Start: 2021-11-03End: 2022-06-28Updated: 2025-02-24

Phase 2

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

CompletedNCT04922021

LEO PharmaAtopic Dermatitis

Start: 2021-07-14End: 2022-09-26Updated: 2025-03-13

Related Papers

Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results.

2025-11-11